Abstract
Background: Many studies have shown that endothelial progenitor cell (EPC) can enhance the neovascularization of the ischemic myocardium. Peripheral blood and bone marrow are the most convenient resources for EPC.
Objective: The aim of the study was to investigate, in vitro and in vivo, the different biological properties between circulating EPC (CEPC) and bone marrow EPC (BM‐EPC) of AMI rats.
Methods: The proliferative, migrative, adherent and angiogenic properties were investigated in vitro. 1 × 106 CEPCs, 1 × 106 BM-EPCs and medium (EBM-2) were injected in the myocardium of AMI rats. Echocardiography, regional myocardial blood flow (RMBF), capillary density and Y chromosome fluorescence in situ hybridization (FISH) were performed at 4 weeks after transplantation.
Results: The CEPCs had higher proliferative, migrative, adherent capabilities and lower senescent ratio, could adhere more quickly to fibronectin than BM-EPCs. CEPCs could form capillary-like structures whereas BM-EPCs did not show similar structures on Matrigel. In vivo, transplanted CEPCs and BM-EPCs were found in cardiac tissue by FISH. CEPCs treatment led to a better cardiac function, RMBF and capillary density than BM-EPCs.
Conclusion: Different biological properties were observed between CEPCs and BM-EPCs. Autologous CEPCs are more suitable for the AMI rat.
Key words
endothelial progenitor cells - bone marrow - circulating - acute myocardial infarction
References
-
1
Krupnick A S, Balsara K R, Kreisel D. et al .
Fetal liver as a source of autologous progenitor cells for perinatal tissue engineering.
Tissue Eng.
2004;
10
723-735
-
2
Cao Y, Sun Z, Liao L. et al .
Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo.
Biochem Biophys Res Commun.
2005;
332
370-379
-
3
Wu K H, Zhou B, Lu S H. et al .
In vitro and in vivo differentiation of human umbilical cord derived stem cells into endothelial cells.
J Cell Biochem.
2007;
100
608-616
-
4
Gehling U M, Ergun S, Schumacher U. et al .
In vitro differentiation of endothelial cells from AC133-positive progenitor cells.
Blood.
2000;
95
3106-3112
-
5
Tatsumi T, Matsubara H.
Therapeutic angiogenesis for peripheral arterial disease and ischemic heart disease by autologous bone marrow cells implantation.
Nippon Rinsho.
2006;
64
2126-2134
-
6
Stamm C, Kleine H D, Westphal B. et al .
CABG and bone marrow stem cell transplantation after myocardial infarction.
Thorac Cardiovasc Surg.
2004;
52
152-158
-
7
Kawamoto A, Asahara T, Losordo D W.
Transplantation of endothelial progenitor cells for therapeutic neovascularization.
Cardiovasc Radiat Med.
2002;
3
221-225
-
8
Le Ricousse-Roussanne S, Barateau V, Contreres J O. et al .
Ex vivo differentiated endothelial and smooth muscle cells from human cord blood progenitors home to the angiogenic tumor vasculature.
Cardiovasc Res.
2004;
62
176-184
-
9
Madeddu P.
Therapeutic angiogenesis and vasculogenesis for tissue regeneration.
Exp Physiol.
2005;
90
315-326
-
10
Rehman J, Li J, Orschell C M. et al .
Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors.
Circulation.
2003;
107
1164-1169
-
11
Gu J, Wang C Q, Fan H H. et al .
Effects of resveratrol on endothelial progenitor cells and their contributions to reendothelialization in intimal-injured rats.
J Cardiovasc Pharmacol.
2006;
47
711-721
-
12
Schachinger V, Assmus B, Honold J. et al .
Normalization of coronary blood flow in the infarct-related artery after intracoronary progenitor cell therapy: intracoronary Doppler substudy of the TOPCARE‐AMI trial.
Clin Res Cardiol.
2006;
95
13-22
-
13
Iwasaki H, Kawamoto A, Ishikawa M. et al .
Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction.
Circulation.
2006;
113
1311-1325
-
14
Bompais H, Chafraoui J, Canron X. et al .
Human endothelial cells derived from circulating progenitors display specific functional properties compared with mature vessel wall endothelial cells.
Blood.
2004;
103
2577-2584
-
15
Hur J, Yoon C H, Kim H S. et al .
Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis.
Arterioscler Thromb Vasc Biol.
2004;
24
288-293
-
16
Gulati R, Jevremovic D, Peterson T E. et al .
Diverse origin and function of cells with endothelial phenotype obtained from adult human blood.
Circ Res.
2003;
93
1023-1025
-
17
Massa M, Rosti V, Ferrario M. et al .
Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction.
Blood.
2005;
105
199-206
-
18
Tang J, Xie Q, Pan G. et al .
Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion.
Eur J Cardiothorac Surg.
2006;
30
353-361
-
19
Murayama T, Tepper O M, Silver M. et al .
Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo.
Exp Hematol.
2002;
30
967-972
-
20
Fang N T, Xie S Z, Wang S M. et al .
Construction of tissue-engineered heart valves by using decellularized scaffolds and endothelial progenitor cells.
Chin Med J.
2007;
120 (8)
696-702
-
21
Verma S, Kuliszewski M A, Li S H. et al .
C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease.
Circulation.
2004;
109
2058-2067
-
22
Matsuo Y, Imanishi T, Hayashi Y. et al .
The effect of senescence of endothelial progenitor cells on in-stent restenosis in patients undergoing coronary stenting.
Intern Med.
2006;
45
581-587
-
23
De Angelis K, Ogawa T, Sanches I C. et al .
Impairment of cardiac output and blood flow adjustments to exercise in L-NAME-induced hypertensive rats.
J Cardiovasc Pharmacol.
2006;
47
371-376
-
24
Kawamoto A, Tkebuchava T, Yamaguchi J. et al .
Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia.
Circulation.
2003;
107
461-468
-
25
Kocher A A, Schuster M D, Szabolcs M J. et al .
Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function.
Nat Med.
2001;
7
430-436
-
26
Kajiguchi M, Kondo T, Izawa H. et al .
Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia.
Circ J.
2007;
71
196-201
-
27
Murayama T, Tepper O M, Silver M. et al .
Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo.
Exp Hemato.
2002;
30
967-972
-
28
Cuevas P, Barrios V, Giménez-Gallego G. et al .
Serum levels of basic fibroblast growth factor in acute myocardial infarction.
Eur J Med Res.
1997;
28
282-284
-
29
Kawamoto A, Kawata H, Akai Y. et al .
Serum levels of VEGF and basic FGF in the subacute phase of myocardial infarction.
Int J Cardiol.
1998;
67
47-54
-
30
Fontaine V, Filipe C, Werner N. et al .
Essential role of bone marrow fibroblast growth factor-2 in the effect of estradiol on reendothelialization and endothelial progenitor cell mobilization.
Am J Pathol.
2006;
169
1855-1862
-
31
Ben-Shoshan J, George J.
Endothelial progenitor cells as therapeutic vectors in cardiovascular disorders: from experimental models to human trials.
Pharmacol Ther.
2007;
115
25-36
-
32
Cao R, Eriksson A, Kubo H. et al .
Comparative evaluation of FGF‐2-, VEGF‐A-, and VEGF‐C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability.
Circ Res.
2004;
94
664-670
-
33
Satoru N, Hiroshi N, Yoko T, Go W.
Protective effect of basic fibroblast growth factor against myocyte death and arrhythmias in acute myocardial infarction in rats.
Circ J.
2003;
67
334-339
Prof. Wei Meng
Shanghai Sixth Hospital, Shanghai JiaoTong University School of Medicine
The Division of Cardiology
No. 600, Yishan Road
200233 Shanghai
China
Fax: + 86 21 64 70 19 32
Email: drweimeng@hotmail.com
